Trial Profile
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Dordaviprone (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Chimerix
- 03 Oct 2023 Results (n=22) assessing the efficacy of ONC201 at the recommended phase II dose (RP2D) in patients with recurrent or refractory metastatic breast or endometrial cancer published in the Oncologist.
- 08 Oct 2021 Status changed from active, no longer recruiting to completed.
- 06 Nov 2020 Status changed from recruiting to active, no longer recruiting.